Only days ago the Burzynski Research Institute, Inc. (BRI) released a statement to the media explaining that the U.S. Food and Drug Administration (FDA) has finally ended their latest attempt to stifle his lifetime’s work and a breakthrough that will likely revolutionize the way cancer is viewed and treated. Surprisingly lifting a two-year partial clinical hold on an Investigational New Drug (IND) application for Antineoplastons A10/AS2-1 Injections and clearing the way for long-awaited Phase 3 trials for newly-diagnosed cancer patients, initially for a specific form of cancer known as Diffuse Intrinsic Brainstem Glioma. Which, considering the already proven success rates prior to the government hold, on both Glioma during Phase 2 trials and many other forms of cancer individually, is likely soon to silence most of the naysayers, critics and skeptics and give a much needed booster to an industry that has been suffering from almost total corruption and manipulation of the Hippocratic Oath for a very, very long time.
Posted on: Tue, 08 Jul 2014 02:32:16 +0000
Trending Topics
Recently Viewed Topics
© 2015